Can investing in infectious disease pay off? Vir shows its a struggle
Nearly a decade ago, venture capitalist Bob Nelsen pitched industry veteran Vicki Sato on launching a company dedicated to tackling pathogens. Sato initially thought it was a crazy idea, as biotech companies had been moving away from infectious disease research. Despite being retired, Sato loved the clarity of chasing pathogens and had experience in HIV…